Skip to main content
NCBI home page
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Cancer Prev Res (Phila). 2015 Apr 23;8(7):628–635. doi: 10.1158/1940-6207.CAPR-14-0449

Effect of Vitamin D3 supplementation in combination with weight loss on inflammatory biomarkers in postmenopausal women: a randomized controlled trial

Catherine Duggan 1, Jean de Dieu Tapsoba 1, Caitlin Mason 1, Ikuyo Imayama 1, Larissa Korde 1,2, Ching-Yun Wang 1,2, Anne McTiernan 1,2
PMCID: PMC4491001  NIHMSID: NIHMS685367  PMID: 25908506

Abstract

Obesity and vitamin D deficiency are associated with risk for several cancers, possibly through inflammation and adipokine-related pathways. 218 postmenopausal women with BMI>25 kg/m2 and low serum 25-hydroxyvitamin D (25(OH)D; ≥10-<32 ng/mL), were randomized to 12-months of either (i) weight-loss intervention + 2000 IU/day oral vitamin D3 or (ii) weight-loss intervention + daily placebo. Serum adiponectin, leptin, tumor necrosis factor-alpha (TNF-α), Interleukin (IL)-6; IL-1β; IL-8 and IL-10, were measured by immunoassay, and a composite inflammatory biomarker score calculated. Using generalized estimating equations, mean changes in outcomes were compared between arms (intent-to-treat), adjusted for possible confounders. Analyses were also stratified by weight-loss (gained/no weight-loss; <5%; 5-10%; ≥10%). At 12-months, there were no significant differences in analyte changes between arms. In stratified analyses, participants randomized to vitamin D3who lost 5-10% of baseline weight, vs. participants who gained weight/had no weight-loss, had significantly greater decreases in levels of IL-6 compared to those randomized to placebo: absolute change -0.75 pg/mL (-17.2%) Placebo vs. -1.77 pg/mL (-37.3%) Vitamin D, P=0.004. Similar but attenuated results were observed for participants who lost ≥10% of baseline weight: -0.41 pg/mL (-13.6%) Placebo vs. -0.67 pg/mL (-17.3%) Vitamin D, P=0.02. Effects of vitamin D3 supplementation on levels of IL-1β were inconsistent when stratified by weight loss. There were no intervention effects on IL-10, TNF-α, IL-8, the composite score, adiponectin or leptin, when stratified by weight-loss. In conclusion, Vitamin D3 supplementation in combination with weight-loss of at least 5% of baseline weight was associated with significant reductions in levels of IL-6.

Introduction

Overweight and obesity are associated with the risk of developing several types of cancer.(1-3) The underlying mechanisms linking adiposity to cancer risk are still unknown, but it is likely that the tissue microenvironment in the obese state is involved in dysregulation of a number of systems including inflammatory pathways,(4-6) and in the expression of adipokines, secreted by adipose tissue, such as adiponectin and leptin.(7) The inflammatory response is mediated via cytokines, proteins that can either promote (e.g. c-reactive protein (CRP), interleukin (IL)-1β, tumor necrosis factor (TNF)-α) or suppress inflammation (including e.g. IL-10). A variety of pro-inflammatory cytokines including IL-1β and IL-6 have been implicated in the etiology of cancer.(8-12) Adiponectin is a peptide hormone with levels inversely correlated to body mass index (BMI).(13) It has insulin-sensitizing, anti-angiogenic, and anti-inflammatory effects.(14, 15) Leptin is a hormone that regulates appetite, food intake, and body weight. Both adiponectin and leptin play a central role in energy homeostasis, metabolism, and regulation of adiposity.(16, 17)

The definitions of vitamin D [25-hydroxyvitamin D (25(OH)D)] deficiency and insufficiency have been debated,(18) with classifications for ‘deficiency’ ranging from <10 ng/mL to <20 ng/mL.(19-21) The Workshop Consensus for Vitamin D Nutritional Guidelines estimated that between 50-60% of older populations worldwide are vitamin D deficient.(19-21) A recent meta-analysis and systematic review of both observational cohort studies of circulating 25(OH)D, and randomized clinical trials of vitamin D supplementation, reported inverse associations of circulating 25(OH) D with risk of death due to cardiovascular disease, cancer, and other causes, as well as reduced overall mortality with Vitamin D3 supplementation.(22) Furthermore, several investigations suggest that vitamin D deficiency may be associated with increased levels of circulating inflammatory markers.(23-26)

Several studies have reported that weight loss is associated with reductions in inflammation and in adipokines: in a previous randomized controlled trial (RCT), a behavioral weight-loss intervention significantly reduced circulating CRP, serum amyloid A, and IL-6; increased adiponectin, and decreased leptin.(27, 28) However, whether vitamin D administration can increase the effect of weight loss on inflammation-related biomarkers and adipokines is unknown.

This study is ancillary to the Vitamin D diet and Activity (ViDA) clinical trial which randomized overweight/obese, 25(OH)D insufficient (i.e. ≥10 to <32 ng/mL), postmenopausal, healthy women to one year of 2000 IU oral vitamin D3 supplementation daily vs. daily placebo. All randomized women underwent a concomitant weight-loss (diet + exercise) program, with a goal of 10% weight loss. We reported previously that levels of CRP decreased significantly with increasing serum 25(OH)D change from baseline to 12-months, adjusted for change in weight, only among the 55% of participants whose study medication adherence data was available.(29)

The primary aims of this study are to examine, in the context of a completed RCT, whether 2000 IU oral Vitamin D supplementation in combination with a weight-loss program, reduces serum levels of leptin or the pro-inflammatory cytokines TNF-α, IL-6, IL-1β and IL-8; or increases levels of adiponectin or the anti-inflammatory marker IL-10, compared to a weight-loss program+placebo in post-menopausal overweight or obese women who had insufficient levels of 25(OH)D at baseline. In preplanned analyses, we also stratified analyses by categories of weight change.

Materials and Methods

This study is ancillary to the ViDA study (Trial Registration: www.clinicaltrials.gov Identifier NCT01240213) a randomized clinical trial comparing the effects of 12 months of 2000 IU/day oral Vitamin D (cholecalciferol or vitamin D3) supplementation vs. placebo on weight and other biomarkers of breast cancer risk in overweight and obese postmenopausal women partaking in a lifestyle based weight-loss program.

The study was performed with the approval of the Fred Hutchinson Cancer Research Center Institutional Review Board, in accordance with an assurance filed with and approved by the U.S. Department of Health and Human Services. Written informed consent was obtained from each participant.

Study Population

The study has been described in detail elsewhere.(29) Briefly, 218 postmenopausal, overweight or obese (BMI≥25 kg/m2), aged 50-75, not taking hormonal therapy, with insufficient serum 25(OH)D concentrations (i.e. ≥10 to <32 ng/mL), were enrolled between 2010-2012, and randomly assigned to a 1-year intervention arm consisting of 2000 IU/day of oral vitamin D3 supplementation + a lifestyle based weight-loss program (n=109; ‘Vitamin D’); or to a control arm of a daily placebo+ a life-style based weight-loss program (n=109; ‘Placebo’). Ineligibility criteria included contraindications to taking >2000 IU vitamin D3/day; already participating in a diet or exercise intervention; history of bariatric surgery; use of weight loss medications; or serum 25(OH)D<10 ng/mL (‘deficient’) and ≥32 ng/mL (‘replete’). Randomization was stratified according to BMI (<30 kg/m2 or ≥30 kg/m2) and consent for optional breast and abdominal subcutaneous fat biopsies. The number of women randomized to each study arm did not differ by season (χ2 p>0.99). All staff except study statisticians were blinded to randomization status. Eighty-six percent of women returned for their 12-month appointment to provide biospecimens and survey data (N=94, Placebo arm; N=93, Vitamin D arm). Of these women only 55% remembered to return their unused pills. Thus, complete pill counts are available only for a subset of women: 54% of women in the vitamin D arm and 56% of women in the placebo arm. Of these, vitamin D-randomized women consumed 98% of capsules compared with 96% in placebo-randomized women. At baseline, 59 (27.1%) women reported taking Vitamin D supplements on a regular basis, compared to 41 (21.8%) at 12-months. The 12-month change in vitamin D intake from supplements did not differ between study arms (p=0.60)

Weight Loss Program

The ViDA lifestyle-based weight-loss program was administered to all participants. It included a diet and exercise component, with a weight-loss goal of 10% of participants' baseline weight, which was adapted from a successful intervention that we have previously used in a similar population of overweight and obese postmenopausal women, (30) based upon the Diabetes Prevention Program and Look Ahead lifestyle change weight loss programs.(31, 32).

The goals of the diet program were: total daily energy intake of 1200-2000 kcal/day based on baseline weight, less than 30% daily energy intake from fat, and a 10% reduction in body weight by 6 months with maintenance thereafter to 12 months. The nutrition program, led by behaviorally-trained registered dieticians, was delivered in groups and individual sessions.

The goal of the exercise program was: ≥45 minutes of moderate-to-vigorous intensity exercise, 5 days per week (225 min/week) for 12 months. Women attended two sessions per week at our study facility where they were supervised by an exercise physiologist, and performed their remaining sessions at home. Facility-based exercise consisted of treadmill walking or jogging, stationary bicycling, and use of other aerobic machines, while a variety of home exercises were encouraged including walking/hiking, aerobics, and bicycling.

Blood Specimen Collection and Processing

At baseline and 12 months, participants provided a 12-hour fasting 50 mL sample of blood, which was processed within 1 hour of collection and stored at −70°C. Participants were instructed to refrain from alcohol (48 hours) and vigorous exercise (24 hours) prior to clinic appointments. Of 218 participants randomized, baseline and 12-month serum was available for 187 (86%) participants (93 control; 94 intervention).

Assays

Serum levels of TNF-α, IL-6, IL-1β, IL-8 and IL-10 were assayed at the Dept. of Laboratory Medicine, University of Washington (UW), Seattle, WA, using Milliplex Map Human High Sensitivity T Cell Panel, Immunology Multiplex Assay (EMD Millipore Corp., Billerica MA). Internal QA samples containing high and low levels of each analyte were included in each assay to assess the intra-assay coefficient of variation (CV). Baseline and 12-month samples from each individual were included in the same batch, and participants' samples were randomly placed across batches. Laboratory personnel were blinded with regard to participant and QA sample identity. The intra-assay CVs for each assay for high and low concentrations respectively were as follows: TNF-α, 22.6% and 31.9%; IL-1β, 18.7% and 29.4%; IL-8, 24.9% and 39.5%; IL-10, 29.4% and 20.5%;and IL-6, 36.4%% and 41.8%. Inter-assay CVs were: TNF-α, 14.4%; IL-1β, 22.92%; IL-8, 24.3%; IL-10, 25.91%; and IL-6, 25.5%. Serum levels of adiponectin and leptin were measured at the Northwest Lipid Research Laboratory at the UW using commercially immunoassays (Millipore Inc., Billerica, MA), with CVs of 8.4% and 8.8% (adiponectin) and 9.1% and 14.3% (leptin), respectively. Serum levels of 25(OH)D were measured as previously described.(33)

Covariates

Demographics, lifestyle behaviors such as sun-exposure and dietary intake, physical activity, medical history and supplement use were collected by questionnaire; anthropometrics were measured and BMI was calculated as kg/m2, at baseline and 12 months. Total and percentage body fat and trunk fat mass was measured by a DXA whole-body scanner (GE Lunar, Madison, WI). We generated an inflammatory biomarker composite z-score of all of the pro- and anti-inflammatory markers combined as described by Hopkins et al. (34) Briefly, a normalized z-score for each biomarker value, with a mean of zero and standard deviation of 1.0, was calculated as z = (x − μ)/σ, where x is a participant's biomarker value at a given visit, and μ and σ are the study population mean and standard deviation, respectively, at baseline. The combined z-score for each participant at each trial visit was created by summing the z-scores of each inflammatory marker. IL-10 was subtracted as it is classified as an anti-inflammatory cytokine. Inclusion of previously measured CRP (33) in the biomarker score had no effect on the results, and was omitted. Medication use known to have effects on CRP and other inflammatory markers, such as (1) systemic corticosteroids and (2) either ACE (angiotensin-converting enzyme) inhibitors, statins, or NSAIDs (non-steroidal anti-inflammatories),(35) were coded as use/non-use at baseline and 12 months.

Statistical Analyses

One participant was omitted from the analysis as she was missing baseline serum measurements. A natural logarithmic transformation was applied to the outcome variables to improve the normality of the distribution.

Mean changes in IL-6, IL-1β, IL-10, IL-8, TNF-α, the inflammatory composite score, and adiponectin and leptin, from baseline to 12 months, stratified by study arm, were computed. The intervention effect on these variables was examined based on the assigned treatment at randomization, regardless of adherence or study retention (i.e. intent-to-treat). Mean 12-month changes in the vitamin D group were compared to placebo using the generalized estimating equations modification of linear regression to account for intra-individual correlation over time.

Changes in weight were calculated and used to stratify observed changes in analytes between arms at 12 months. Weight-loss was categorized as no change/gained any weight (referent); lost <5% of baseline weight; lost ≥5-<10% of baseline weight; and lost ≥10% of baseline weight.

All models are presented as unadjusted; and adjusting for age, race/ethnicity, baseline serum 25(OH)D, baseline BMI, vitamin D intake (diet+supplement), calcium intake (diet+supplement), average sun exposure and medication use (use of either corticosteroids and/or CRP-lowering agents). Results are presented as (1) percent change, calculated as 100*(Follow up geometric mean – Baseline geometric mean)/Baseline geometric mean; (2) Absolute treatment effect, calculated as (Absolute change in Vitamin D group - Absolute change in Placebo group); and (3) Relative treatment effect, calculated as (Follow-up geometric mean in Vitamin D group)* (Baseline geometric mean in Placebo group)/[(Baseline geometric mean in Vitamin D group)* (follow up geometric mean in Placebo group)]

All statistical tests were two sided. Statistical analyses were performed using SAS software (version 9, SAS Institute Inc., Cary, NC).

Results

At baseline, participants were on average aged 59.6 years, with a mean BMI of 32.4 kg/m2 (Table 1). The majority were non-Hispanic white (86.2%), and the average baseline serum 25(OH)D level was 21.4 (s.d.6.1) ng/mL. As previously reported, a total of 86% of participants completed their 12-month measurements. Serum 25(OH)D increased by a mean of 13.6 (95% CI: 11.6, 15.4) ng/mL in the vitamin D arm while it decreased by a mean 1.3 (95% CI: -2.6, -0.3) ng/mL in the placebo arm (P < 0.0001). Changes in weight, BMI, waist circumference, percentage body fat, insulin and CRP were similar between groups (all P>0.05).(29)

Table 1. Selected baseline characteristics of study participants.

Variable All Participants Intervention Arms
Placebo Vitamin D
N Mean (s.d.) N Mean (s.d.) N Mean (s.d.)
Age (years) 218 59.6 (5.1) 109 59.0 (4.7) 109 60.3 (5.3)
Weight (kg) 218 87.7 (16.3) 109 88.1 (17.1) 109 87.4 (15.5)
BMI (kg/m2) 218 32.4 (5.8) 109 32.5 (6.1) 109 32.3 (5.5)
Waist circumference (cm) 218 100.1 (12.3) 109 100.3 (13.5) 109 100.0 (11.0)
Body fat (%) 215 47.4 (4.9) 107 47.5 (4.5) 108 47.3 (5.2)
Moderate to vigorous physical activity (min/week) 218 142.2 (143.2) 109 146.6 (140.4) 109 137.9 (146.5)
Caloric intake (kcal/d)a 206 2004 (699.3) 103 1982 (678.4) 103 2025 (722.3)
Relative % calories from fat a 206 33.0 (6.2) 103 32.6 (5.7) 103 33.4 (6.7)
Relative % calories from protein a 206 17.6 (3.2) 103 17.9 (3.5) 103 17.2 (2.9)
Relative % calories from carbohydrate a 206 48.3 (7.4) 103 48.1 (7.1) 103 48.5 (7.8)
Dietary vitamin D intake (μg) 206 6.6 (4.6) 103 6.9 (5.2) 103 6.3 (4.0)
Vitamin D supplement intake (IU) at baseline 52 280.0 (134.5) 22 303.6 (125.2) 30 262.7 (140.5)
Total calcium intake (mg) 208 1120 (599.8) 103 1170 (632.7) 105 1071 (564.4)
Sun exposure (hrs/wk) 218 2.4 (1.3) 109 2.2 (1.3) 109 2.5 (1.3)
Serum 25(OH)D (ng/mL) 218 21.4 (6.1) 109 21.4 (6.1) 109 21.4 (6.2)
IL-1β (pg/mL) 217 1.5 (10.4) 108 1.0 (3.0) 109 2.0 (14.4)
IL-6 (pg/mL) 217 7.2 (19.8) 108 8.6 (27.2) 109 5.7 (7.1)
IL-8 (pg/mL) 217 13.5 (64.9) 108 7.6 (5.1) 109 19.4 (91.2)
IL-10 (pg/mL) 217 53.7 (386.6) 108 28.9 (33.2) 109 78.3 (544.5)
TNF-α (pg/mL) 217 10.4 (4.7) 108 10.4 (4.8) 109 10.4 (4.6)
Adiponectin (μg/mL) 217 12.4 (6.1) 108 12.5 (6.4) 109 12.3 (5.9)
Leptin (ng/mL) 217 40.3 (18.9) 108 40.3 (17.4) 109 40.4 (20.5)
N (%) N (%) N (%)
Race/Ethnicity
 Non-Hispanic white 188 (86.2) 94 (86.2) 94 (86.2)
 Non-Hispanic Black 13 (6.0) 6 (5.5) 7 (6.4)
 Hispanic 5 (2.3) 4 (3.7) 1 (0.9)
 Other (American Indian, Asian or Unknown) 12 (5.5) 5 (4.5) 7 (6.4)
Medication Useb
 Systemic corticosteroids
  Baseline 11 (5.0) 6 (5.5) 5 (4.6)
  12 Months 7 (3.2) 3 (2.8) 4 (3.7)
 CRP-lowering agentsc 11 (5.0) 6 (5.5) 5 (4.6)
  Baseline 6 (2.8) 1 (0.9) 5 (4.6)
  12-months 11 (5.0) 6 (5.5) 5 (4.6)
Open in a new tab
a

Dietary data (FFQs) available for all participants at baseline (N=218) but values derived from FFQ were truncated at <600 kcal and >4000 kcal

b

Only one participant was using both corticosteroid and CRP lowering agent medication simultaneously at baseline. No participant used both medication types simultaneously at 12 months.

c

Statins, NSAIDs, ACE inhibitors

While there was a reduction in levels of all analytes comparing baseline and 12 months, there were no significant differences in the magnitude of these changes between arms (Table 2). We examined the effect of removing outlying data points that corresponded to values >99th percentile from the analyses. Three participants had IL-1β levels classified as outliers; 3 had IL-8 or TNF-α classified as outliers (values ≥99th percentile), and 4 had IL-6 or IL-10 classified as outliers. Removal of these data had no effect on the results (data not shown).

Table 2. Twelve-month changes in serum IL-1β, IL-6, IL-8, IL-10, TNF-α, BMI, adiponectin and leptin, and in the inflammatory biomarker score, by study arm.

Variable Placebo Vitamin D Absolute
treatment
effectd
(95% CI)		 Relative
treatment
effecte
(95% CI)		 P-value
Baseline
N=109		 12 month
N=94		 Change Baseline
N=109		 12 month
N=93		 Change
Geometric
Mean (95%
CI)		 Geometric
Mean (95% CI)		 Absolute
Change
(%)		 Geometric
Mean (95% CI)		 Geometric Mean
(95% CI)		 Absolute
Change
(%)		 Pa Pb
BMI kg/m2 (29) (s.d.) 32.5 (6.1) 29.7 (6.1) -2.8 (-8.8) 32.3 (5.5) 29.5 (5.6) -2.8 (-8.7) 0.05 (-0.93, 1.03) 1.0 (0.97, 1.03) 0.63 0.82
IL-1β (pg/mL) 0.14 (0.10, 0.22) 0.12 (0.08, 0.19) -0.02 (-15.9) 0.11 (0.08, 0.16) 0.09 (0.06, 0.15) -0.02 (-16.7) 0 (-0.04, 0.05) 0.99 (0.7, 1.4) 0.28 0.12
IL-6 (pg/mL) 3.89 (3.15 4.79) 3.52 (2.81, 4.42) -0.36 (-9.3) 3.89 (3.33, 4.53) 3.41 (2.82, 4.12) -0.48 (-12.3) -0.12 (-0.92, 0.69) 0.97 (0.78, 1.2) 0.71 0.89
IL-8 (pg/mL) 6.38 (5.72, 7.12) 5.89 (5.12, 6.78) -0.49 (-7.7) 6.64 (5.66, 7.80) 6.30 (5.50, 7.21 -0.34 (-5.2) 0.15 (-0.92, 1.13) 1.03 (0.87, 1.21) 0.93 0.65
IL-10 (pg/mL) 16.46 (13.04, 20.77) 14.47 (10.87, 19.26) -1.99 (-12.1) 16.74 (13.43, 20.87) 15.02 (11.75, 19.20 -1.72 (-10.3) 0.27 (-4.42, 4.66) 1.02 (0.76, 1.36) 0.60 0.71
TNF-α (pg/mL) 9.35 (8.54, 10.24) 8.85 (7.94, 9.85) -0.51 (-5.4) 9.30 (8.45,10.24) 9.14 (8.31, 10.05 -0.16 (-1.8) 0.34 (-0.81, 1.50) 1.04 (0.92, 1.18) 0.41 0.57
Inflammatory Biomarker Scorec 1.05 (0.66-1.67) 0.78 (0.47-1.31) -0.27 (-25.7) 0.96 (0.61, 1.51) 0.76 (0.47-1.21) -0.21 (-21.5) 0.06 (-0.45, 0.57) 1.06 (0.62,1.79) 0.79 0.51
Adiponectin (μg/mL) 11.04 (10.0-12.8) 11.85 (10.71, 13.1) 0.81 (7.3) 11.11 (10.19, 12.14) 12.12 (11.10, 13.24) 1.01 (9.1) 0.2 (-0.68, 1.07) 1.02 (0.94, 1.10) 0.33 0.61
Leptin (ng/mL) 36.17 (32.88, 39.78) 24.62 (21.27, 28.49) -11.5 (-31.9) 35.59 (32.27, 39.24) 23.5 (20.07, 27.61) -12.0 (-33.9) 0.50 (-4.51, 3.45) 0.97 (0.83, 1.14) 0.69 0.73
Open in a new tab
a

P-value was obtained from GEE model comparing 12- month change between vitamin D and placebo groups adjusted for baseline BMI.

b

P-value was obtained from GEE model adjusting for age, ethnicity, baseline serum 25(OH)D, baseline BMI, Vitamin D intake (diet+supplement), Calcium intake (diet+supplement), medication use, and average sun exposure.

c

The inflammatory biomarker score was calculated as described (29) using log-transformed IL-1 β, IL-6, IL-8, IL-1 0 and TNF-α

d

Absolute treatment effect was calculated as (Absolute change in Vitamin D group - Absolute change in Placebo group).

e

Relative treatment effect was calculated as (Follow up geometric mean in Vitamin D group)* (Baseline geometric mean in Placebo group)/[(Baseline geometric mean in Vitamin D group)* (follow up geometric mean in Placebo group)]

We stratified women by degree of weight-loss, using cut points shown to have clinical significance(36) (loss of <5%; 5-10%; and ≥10% of baseline weight) compared to participants who experienced no change/gained weight (the referent group; Table 3). Changes in levels of analytes by randomization arm within each weight strata were compared to the referent group, adjusting for age, ethnicity, baseline serum 25(OH)D, vitamin D intake (diet+supplement), calcium intake (diet+supplement), medication use and average sun exposure.

Table 3. Twelve-month changes in serum IL-1β, IL-6, IL-8, IL-10, TNF-α, an Inflammatory Biomarker Score, and Adiponectin and Leptin, by study arm' stratified by percent weight loss.

Weight Loss Placebo Vitamin D Absolute
treatment
effectc
(95% CI)		 Relative
treatment
effectd
(95% CI)		 P valuea P valueb
Baseline
N=94
Geometric
Mean
(95% CI)		 12 month
N=94
Geometric
Mean
(95% CI)		 Absolute
Change
(%)		 Baseline
N=94
Geometric
Mean
(95% CI)		 12 month
N=93
Geometric
Mean
(95% CI)		 Absolute
Change
(%)
IL-1β (pg/mL)
No change/gained weight 0.11 (0.03, 0.51) 0.07 (0.03, 0.18) -0.04 (-35.9) 0.10 (0.03, 0.27) 0.19 (0.06, 0.60) 0.10 (102.5) 0.14 (0.01-0.52) 3.16 (1.06-11.23) Ref. Ref.
Lost <5% baseline weight 0.16 (0.06, 0.43) 0.13 (0.05, 0.35) -0.03 (-17.9) 0.18 (0.07, 0.45) 0.17 (0.08, 0.40) -0.01 (-1.6) 0.02 (-0.09, 0.13) 1.2 (0.73, 2.01) 0.15 0.03
Lost 5-10% baseline weight 0.16 (0.07, 0.36) 0.10 (0.04, 0.27) -0.06 (-36.4) 0.08 (0.04, 0.16) 0.05 (0.02, 0.13) -0.02 (-27.7) 0.04 (-0.02, 0.12) 1.14 (0.67, 1.98) 0.13 0.02
Lost ≥10% baseline weight 0.15 (0.07, 0.30) 0.15 (0.08, 0.29) 0.00* (1.6) 0.08 (0.04, 0.17) 0.08 (0.04, 0.17) -0.01 (-6.0) -0.01 (-0.07, 0.93) 0.93 (0.57, 1.49) 0.06 0.008
IL-6 (pg/mL)
No change/gained weight 6.17 (2.53, 15.05) 4.30 2.13, 8.70) -1.87 (-30.3) 3.76 (2.52, 5.62) 4.59 (2.88, 7.33) 0.83 (22.2) 2.7 (0.03, 8.64) 1.75 (1.00, 3.19) Ref. Ref.
Lost <5% baseline weight 4.43 (2.88, 6.82) 4.51 3.14, 6.48) 0.08 (1.9) 3.65 (2.60, 5.14) 3.80 (2.66, 5.42) 0.14 (3.9) 0.06 (-1.43, 1.79) 1.02 (0.70, 1.49) 0.12 0.03
Lost 5-10% baseline weight 4.37 (3.12, 6.12) 3.62 (2.25, 5.81) -0.75 (-17.2) 4.76 (3.58, 6.32) 2.98 (1.97, 4.52) -1.77 (-37.3) --1.02 (-2.91, 0.54) 0.76 (0.48, 1.15) 0.02 0.004
Lost ≥10% baseline weight 2.99 (2.10, 4.24) 2.58 (1.74, 3.83) -0.41 (-13.6) 3.89 (2.85, 5.30) 3.22 (2.39, 4.33) -0.67 (-17.3) -0.27 (-1.28, 0.65) 0.96 (0.71, 1.30) 0.07 0.02
IL-8 (pg/mL)
No change/gained weight 6.26 (4.05, 9.66) 5.56 (3.63, 8.53) -0.70 (-11.1) 6.90 (5.35, 8.88) 6.54 (5.16, 8.30) -0.35 (-5.1) 0.34 (-1.82, 2.70) 1.07 (0.77, 1.51) Ref. Ref.
Lost <5% baseline weight 7.62 (6.38, 9.09) 7.43 (6.03, 9.15) -0.19 (-2.5) 8.62 (5.45, 13.62) 7.36 (5.74, 9.42) -1.26 (-14.6) -1.07 (-5.82, 1.35) 0.88 (0.58, 1.20) 0.33 0.53
Lost 5-10% baseline weight 7.19 (5.85, 8.84) 5.74 (4.31, 7.63) -1.45 (-20.2) 6.72 (5.31, 8.50) 5.57 (4.24, 7.32) -1.15 (-17.1) 0.31 (-1.39, 1.95) 1.04 (0.79, 1.38) 0.90 0.56
Lost ≥10% baseline weight 5.45 (4.48, 6.63) 5.02 (3.86, 6.52) -0.43 (-7.9) 6.75 (4.77, 9.56) 6.30 (4.91, 8.08) -0.45 (-6.7) -0.02 (-1.92, 1.46) 1.01 (0.78, 1.34) 0.78 0.83
IL-10 (pg/mL)
No change/gained weight 12.68 (6.41, 25.05) 9.51 (3.25, 27.81) -3.16 (-25.0) 26.03 (15.89, 42.63) 27.82 (18.29, 42.30) 1.79 (6.9) 4.95 (-8.31, 15.68) 1.42 (0.79, 2.78) Ref. Ref.
Lost <5% baseline weight 19.88 (13.47, 29.33) 14.27 (8.29, 24.54) -5.61 (-28.2) 12.55 (7.37, 21.36) 12.77 (7.00, 23.28) 0.22 (1.7) 5.83 (-2.27, 14.73) 1.42 (0.80, 2.64) 0.80 0.79
Lost 5-10% baseline weight 14.04 (9.23, 21.37) 12.28 (6.51, 23.15) -1.77 (-12.6) 18.27 (10.37, 32.18) 12.72 (8.02, 20.18) -5.55 (-30.4) -3.78 (-16.9, 2.52) 0.80 (0.44, 1.29) 0.18 0.09
Lost ≥10% baseline weight 20.24 (13.33, 30.73) 19.46 (13.64, 27.76) -0.78 (-3.9) 17.87 (13.10, 24.36) 15.18 (10.11, 22.80) -2.68 (-15.0) -1.9 (-7.53, 4.56) 0.88 (0.62, 1.24) 0.13 0.06
TNF-α
No change/gained weight 8.18 (6.16, 10.87) 7.94 (6.01, 10.50) -0.24 (-2.9) 7.66 (5.60, 10.48) 8.44 (6.15, 11.58) 0.78 (10.2) 1.01 (-1.6, 4.06) 1.13 (0.82, 1.64) Ref. Ref.
Lost <5% baseline weight 10.32 (8.65, 12.32) 10.53 (8.96 12.38) 0.21 (2.1) 10.56 (8.83, 12.62) 11.55 (10.10, 13.21) 1.00 (9.4) 0.78 (-0.9, 2.46) 1.07 (0.92, 1.26) 0.85 0.33
Lost 5-10% baseline weight 9.69 (8.30, 11.31) 7.75 (6.11, 9.83) -1.94 (-20.1) 9.41 (7.66, 11.54) 8.74 (7.23, 10.58) -0.66 (-7.0) 1.28 (-1.16, 3.87) 1.16 (0.88, 1.6) 0.76 0.57
Lost ≥10% baseline weight 9.68 (8.17, 11.47) 8.74 (7.17, 10.66 -0.94 (-9.7) 9.60 (8.23, 11.19) 8.53 (7.33, 9.92) -1.07 (-11.1) -0.13 (-1.76, 1.41) 0.98 (0.83, 1.17) 0.56 0.12
Inflammatory Biomarker Score
No change/gained weight 1.41 0.80 -0.61 (-43.2) 0.43 0.79 0.36 (84.1) 0.97 (-0.25, 6.26) 3.24 (0.71, 17.43) Ref. Ref.
Lost <5% baseline weight 1.70 2.09 0.39 (-23.1) 2.62 2.58 -0.05 (-1.8) -0.44 (-5.84, 1.54) 0.8 (0.31, 1.97) 0.16 0.05
Lost 5-10% baseline weight 1.81 0.63 -1.18 (-65.2) 0.95 0.45 -0.49 (-52.1) 0.69 (-0.51, 2.91) 1.38 (0.48, 4.47) 0.45 0.09
Lost ≥10% baseline weight 0.59 0.39 -0.21 (-34.7) 0.87 0.57 -0.30 (-34.3) -0.09 (-0.99, 0.47) 1.01 (0.48, 2.06) 0.26 0.06
Adiponectin (μg/mL)
No change/gained weight 13.35 (10.61, 16.80) 13.06 (10.45, 16.33) -0.29 (-2.2) 11.37 (9.24, 13.97) 10.78 (8.79, 13.23) -0.58 (-5.1) -0.29 (-1.27, 0.69) 0.97 (0.90, 1.04) Ref. Ref.
Lost <5% baseline weight 11.61 (9.37, 14.39) 11.56 (9.46, 14.14) -0.05 (-0.4) 12.29 (9.73, 15.52) 12.62 (10.17, 15.65) 0.33 (2.7) 0.38 (-0.73, 1.42) 1.03 (0.94, 1.12) 0.18 0.38
Lost 5-10% baseline weight 10.47 (8.68, 12.63) 11.34 (9.47, 13.59) 0.88 (8.4) 10.84 (9.37, 12.54) 11.22 (9.71, 12.97) 0.39 (3.6) -0.49 (-1.67, 0.60) 0.96 (0.86, 1.06) 0.59 0.36
Lost ≥10% baseline weight 10.29 (8.63, 12.26) 12.04 (9.94, 14.58) 1.75 (17) 10.57 (8.84, 12.65) 13.18 (11.31, 15.37) 2.61 (24.7) 0.85 (-0.45, 2.15) 1.07 (0.96, 1.19) 0.09 0.19
Leptin (ng/mL)
No change/gained weight 46.16 (35.16, 60.61) 46.27 (36.34, 58.93) 0.11 (0.2) 38.84 (29.00, 52.01) 44.24 (31.92, 61.31) 5.40 (13.9) 5.29 (-2.27, 14.19) 1.14 (0.95, 1.35) Ref. Ref.
Lost <5% baseline weight 34.15 (27.24, 42.82) 31.24 (25.77, 37.89) -2.91 (-8.5) 29.67 (23.41, 37.61) 29.61 (23.88, 36.73) -0.05 (-0.2) 2.86 (-2.39, 8.31) 1.09 (0.92, 1.30) 0.60 0.98
Lost 5-10% baseline weight 34.33 (27.99, 42.12) 25.34 (19.46, 33.00) -9.00 (-26.2) 35.77 (29.24, 43.75) 26.24 (20.29, 33.94) -9.53 (-26.6) -0.53 (-4.15, 3.05) 0.99 (0.86, 1.14) 0.15 0.25
Lost ≥10% baseline weight 34.32 (29.56, 39.84) 15.22 (11.72, 19.77) -19.1 (-55.7) 36.18 (30.25, 43.27) 14.85 (11.18, 19.72) -21.3 (-59.0) -2.23 (-7.81, 2.82) 0.93 (0.72, 1.19) 0.13 0.22
Open in a new tab
*

Absolute changes appear as 0.00 due to rounding.

a

P GEE model. P value comparing differences between Vitamin D and Placebo arms, within each weight strata, compared to those participants who had no change/gained weight after 12 months (referent), adjusted for baseline BMI.

b

P GEE model, P value comparing differences between Vitamin D and Placebo arms within each weight strata, compared to those participants who had no change/gained weight after 12 months (referent)., adjusting for age, race/ethnicity, baseline serum 25(OH)D, Vitamin D intake (diet+supplement), Calcium intake (diet+supplement), medication use, and average sun exposure.

c

Absolute treatment effect was calculated as (Absolute change in Vitamin D group - Absolute change in Placebo group).

d

Relative treatment effect was calculated as (Follow up geometric mean in Vitamin D group)* (Baseline geometric mean in Placebo group)/[(Baseline geometric mean in Vitamin D group)* (follow up geometric mean in Placebo group)]

Participants who lost at least 5-10% of their baseline weight in the vitamin D3 arm, significantly reduced IL-6 levels above that of weight-loss alone, compared to the referent group (Table 3): absolute change-0.75 pg/mL (-17.2%) Placebo vs. -1.77 pg/mL (-37.3%) Vitamin D, P=0.004. Similarly, participants who lost ≥10% of their baseline weight randomized to the vitamin D arm, had greater decreases in IL-6 compared to those in the placebo arm: -0.41 pg/mL (-13.6%) Placebo vs. -0.67 pg/mL (-17.3 %) Vitamin D, P=0.02. Effects of vitamin D on IL-1β were inconsistent when stratified by weight loss, but absolute changes across strata were very small. Finally, there were no intervention effects on the anti-inflammatory cytokine IL-10, TNF-α, IL-8, the inflammatory biomarker composite score, adiponectin or leptin, when stratified by weight loss.

We next compared changes in levels of analytes from baseline to 12-month follow-up by intervention arm, stratified by baseline BMI (<30kg/m2, ≥30kg/m2); no statistically significant differences were observed (all P>0.05; data not shown). Similarly, there were no statistically significant changes in levels of analytes between arms, when stratified by baseline levels of serum 25(OH)D (<20 ng/mL, 20-<32 ng/mL; all P>0.05, data not shown).

In an analysis limited to women randomized to vitamin D, there were no significant differences between levels of analytes comparing the 40 women who did not become replete, with 53 women who became replete [i.e., 25(OH)D ≥32 ng/mL] by 12 months (data not shown). Finally, there were no differences between arms, comparing women with and without complete pill counts (data not shown). Exclusion of outliers from any of these analyses had no effect on results.

Discussion

Here we report that a 12-month reduced calorie/increased physical activity weight loss intervention in combination with 2000 IU of vitamin D3 supplementation per day had no overall effect on circulating levels of inflammatory cytokines compared to the same weight loss intervention + placebo. Participants, who lost at least 5-10% of their baseline weight in the vitamin D3 arm, significantly reduced IL-6 levels above that of weight-loss alone. The non-significant trend of a reduction in levels of the anti-inflammatory cytokine IL-10 with vitamin D3 supplementation in combination with increased weight-loss is surprising, but may reflect down regulation of this cytokine in response to less localized inflammation. Weight loss in combination with vitamin D3 supplementation had no effect on levels of IL-8, TNF-α, the composite biomarker score, adiponectin or leptin.

Vitamin D deficiency, which has been associated with increased risk for certain cancers,(37-41) is associated with higher circulating concentrations of several markers of inflammation, including CRP and IL-6. (24-26, 42). It is known that both weight-loss and increased levels of vitamin D3 are associated with reductions in IL-6. We previously reported results from a different randomized controlled trial in overweight or obese postmenopausal women that used a similar behavioral weight-loss intervention as the present study, and which resulted in significant reductions in IL-6 and CRP levels compared to controls.(27) A variety of in vitro studies have demonstrated that the active form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)2D3) inhibits the production of IL-6,(23) possibly by inhibiting p38 via mitogen-activated protein kinase phosphatase 5, which contains a putative vitamin D response element within its promoter that associated with the vitamin D receptor following treatment with 1,25-(OH)2 D3.(43) Of interest, a recent study found that 1,25(OH)2D resulted in a dose-dependent down-regulation of COX-2 expression in murine macrophages under both basal and lipopolysaccharide-stimulated conditions. It also reduced IL-6 and TNF-α secretion by suppression of Akt phosphorylation and NF-κB signaling.(23) Weight loss and vitamin D3 supplementation may act synergistically via different mechanisms to reduce levels of IL-6. Alternatively, weight loss may increase the bioavailability of vitamin D in different tissues. However, in the present study, achieving 25(OH)D repletion (>32 ng/mL) in women randomized to the vitamin D arm was not associated with significant differences in levels of these analytes when compared to women who did not achieve repletion.

A variety of studies have examined the effect of vitamin D supplementation on inflammatory markers in both chronically ill and healthy individuals, with conflicting results.

A six-month 4-arm RCT randomized 131 healthy women who were deficient in Vitamin D, to receive 60,000 IU/week of Vitamin D3 for 8 weeks followed by 60,000 IU/fortnight; calcium; dual supplementation or placebo. The study examined changes in gene expression of Interferon-γ, IL-4 and its antagonist-IL-4δ2, and a variety of transcription factors involved in their regulation, but reported no significant effect of Vitamin D3 supplementation on their expression.(44) Two groups of obese but otherwise healthy adolescents were randomized to receive 4,000 IU of vitamin D3 daily vs. placebo. After 6 months there was no difference between groups in serum levels of CRP, IL-6 or TNF-α, though the authors suggested the study was inadequately powered to detect biologically relevant changes in these 3 markers.(45) A variety of RCTs found no effect on Vitamin D3 supplementation on inflammatory biomarkers. No effect of vitamin D3 supplementation on CRP or IL-6 was observed in a year-long RCT in 305 healthy postmenopausal women aged 60-70 years, comparing 400 IU vs. 1000 IU placebo supplementation.(26) Similarly no effect on CRP levels were found in RCTs comparing 5000 IU/day of Vitamin D3 vs. Vitamin C supplementation on 88 acutely hospitalized patients treated for an average of 8.2 days (46); 7000 IU of vitamin D3 daily vs. placebo of 52 overweight men (>30 kg/m2) and women aged 18-50 years;(26); or in an RCT of 438 overweight/obese subjects, 21-70 years old, randomized to one year of either 40,000 IU/week of vitamin D3, 20,000 IU/week, or placebo for one year The latter study also found no effect on IL-10.(47) Finally, an RCT comparing 3 months of 1000, 2000, or 4000 Vitamin D3 supplementation vs. placebo in 328 African Americans, found no statistically significant effect of supplementation on changes in CRP, IL-6, IL-10, or sTNF-R2.(42)

Sixty-three children and adolescents with inflammatory bowel disease were randomized to receive either 400 IU of vitamin D2/day, or 1000 IU in summer/2000 IU in winter. Participants who received the lower dose had significantly elevated levels of CRP and IL-6 compared to those who received the higher dose CRP 31% vs. 10%, P = 0.04, and IL-6 54% vs. 27%, P = 0.05; respectively.(48) In 267 patients with systemic lupus erythematosus, a chronic multisystem inflammatory autoimmune disease, a year-long supplementation with daily 2000 IU/day of vitamin D3 vs. placebo for 12 months was associated with a reduction in inflammatory markers.(49) Lastly, an RCT which randomized 92 patients with colorectal adenoma to receive either 6 months of 2 g/day calcium and/or 800 IU/day of vitamin D3 vs. placebo. The study reported a significant reduction in the combined inflammatory biomarker score (77%, P=0.003) in the Vitamin D3 group, compared to placebo.(34)

Our previous analysis found no effect of vitamin D3 supplementation on levels of CRP (either overall or to repletion >32 ng/mL).(33) However, we did observe greater reductions in CRP levels with greater increases in vitamin D3, suggesting a possible dose-response effect, although this effect was no longer significant after adjusting for percentage weight loss.

Strengths of our study include its prospective design, the use of a double-blind–controlled intervention, the broad set of inflammatory markers that were evaluated, and the year-long time-frame.

Limitations include the fact that we did not include women with a 25(OH)D concentration <10ng/mL, and that complete pill counts were only available for 55% participants over the course of the study. All participants received a weight-loss intervention, thus we were unable to determine independent effects of vitamin D3 supplementation. Finally our study population was relatively homogeneous, and these results may not be generalizable to other racial/ethnic groups. We used multiplex immunoassays to measure concentrations of these cytokines, and inter- and intra-assay CVs were high. A number of studies have cited this issue as a potential limitation of bead-based multiplex immunoassays, compared to ELISAs (50, 51). However these and other reports state that despite high CV values, excellent correlations were observed between ELISAs for IL-1β, IL-10, IL-6 and TNF-α when compared to multiplex assays including Milliplex (50-55), and have demonstrated that these immunoassays correlated well with ELISA measurements in serum.(54, 55) Finally a study examining the utility of a fluorescent bead-based assay to simultaneously measure a variety of cytokines reported that inter-individual differences outweighed substantial assay variation for these assays.(56)

In conclusion, 12 months of vitamin D3 supplementation in combination with a weight-loss program in overweight or obese postmenopausal women, was not associated with overall reductions in inflammatory cytokines compared to women undergoing a weight-loss program alone. However participants who lost at least 5% of their baseline body-weight, and who were randomized to the vitamin D arm, had significantly greater reductions in IL-6, compared to those randomized to the placebo arm. Further investigations into the relationship between weight-loss, vitamin D3 supplementation and inflammation are warranted.

Acknowledgments

Funding Sources: Breast Cancer Research Foundation 2013-2014; Susan G. Komen for the Cure Scientific Advisory Council Award 2010-12, NIH R03 CA162482-01;Seattle Cancer Consortium Breast Cancer SPORE (P50 CA138293), and Fred Hutchinson/University of Washington Cancer Consortium (all to A. McTiernan) and the Safeway Foundation to (C. Duggan)

Abbreviations

25 (OH) D

25-hydroxyvitamin D

CI

Confidence Interval

BMI

Body Mass Index

TNF-α

Tumor necrosis factor-alpha

IL

Interleukin

RCT

Randomized Control Trial

Footnotes

Trial Registration: www.clinicaltrials.gov Identifier NCT01240213 

Conflict of Interest: The authors have no conflict of interest to disclose.

References

  • 1.Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. Bmj. 2007;335:1134. doi: 10.1136/bmj.39367.495995.AE. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.van den Brandt PA, Spiegelman D, Yaun SS, Adami HO, Beeson L, Folsom AR, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000;152:514–27. doi: 10.1093/aje/152.6.514. [DOI] [PubMed] [Google Scholar]
  • 3.National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity, and health risk. Arch Intern Med. 2000;160:898–904. doi: 10.1001/archinte.160.7.898. [DOI] [PubMed] [Google Scholar]
  • 4.Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7. doi: 10.1038/nature01322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Shalev I, Entringer S, Wadhwa PD, Wolkowitz OM, Puterman E, Lin J, et al. Stress and telomere biology: a lifespan perspective. Psychoneuroendocrinology. 2013;38:1835–42. doi: 10.1016/j.psyneuen.2013.03.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.O'Donovan A, Tomiyama AJ, Lin J, Puterman E, Adler NE, Kemeny M, et al. Stress appraisals and cellular aging: a key role for anticipatory threat in the relationship between psychological stress and telomere length. Brain Behav Immun. 2012;26:573–9. doi: 10.1016/j.bbi.2012.01.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12:160–74. doi: 10.1016/S1470-2045(11)70002-X. [DOI] [PubMed] [Google Scholar]
  • 8.Dinarello CA. Why not treat human cancer with interleukin-1 blockade? Cancer and Metastasis Reviews. 2010;29:317–29. doi: 10.1007/s10555-010-9229-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Apte RN, Krelin Y, Song X, Dotan S, Recih E, Elkabets M, et al. Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour–host interactions. Eur J Cancer. 2006;42:751–9. doi: 10.1016/j.ejca.2006.01.010. [DOI] [PubMed] [Google Scholar]
  • 10.Reed JR, Leon RP, Hall MK, Schwertfeger KL. Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumourigenesis. Breast Cancer Res. 2009;11:R21. doi: 10.1186/bcr2246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Chu WM. Tumor necrosis factor. Cancer Lett. 2013;328:222–5. doi: 10.1016/j.canlet.2012.10.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Mansell A, Jenkins BJ. Dangerous liaisons between interleukin-6 cytokine and toll-like receptor families: a potent combination in inflammation and cancer. Cytokine & growth factor reviews. 2013;24:249–56. doi: 10.1016/j.cytogfr.2013.03.007. [DOI] [PubMed] [Google Scholar]
  • 13.Ryan AS, Nicklas BJ, Berman DM, Elahi D. Adiponectin levels do not change with moderate dietary induced weight loss and exercise in obese postmenopausal women. Int J Obes Relat Metab Disord. 2003;27:1066–71. doi: 10.1038/sj.ijo.0802387. [DOI] [PubMed] [Google Scholar]
  • 14.Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol. 2002;13:51–9. doi: 10.1097/00041433-200202000-00008. [DOI] [PubMed] [Google Scholar]
  • 15.Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev. 2004;5:153–65. doi: 10.1111/j.1467-789X.2004.00142.x. [DOI] [PubMed] [Google Scholar]
  • 16.Ganz PA. Survivorship: adult cancer survivors. Primary care. 2009;36:721–41. doi: 10.1016/j.pop.2009.08.001. [DOI] [PubMed] [Google Scholar]
  • 17.Forsythe LP, Kent EE, Weaver KE, Buchanan N, Hawkins NA, Rodriguez JL, et al. Receipt of psychosocial care among cancer survivors in the United States. J Clin Oncol. 2013;31:1961–9. doi: 10.1200/JCO.2012.46.2101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Ashing-Giwa K, Rosales M, Lai L, Weitzel J. Depressive symptomatology among Latina breast cancer survivors. Psychooncology. 2013;22:845–53. doi: 10.1002/pon.3084. [DOI] [PubMed] [Google Scholar]
  • 19.Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–81. doi: 10.1056/NEJMra070553. [DOI] [PubMed] [Google Scholar]
  • 20.Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84:18–28. doi: 10.1093/ajcn/84.1.18. [DOI] [PubMed] [Google Scholar]
  • 21.Norman AW, Bouillon R, Whiting SJ, Vieth R, Lips P. 13th Workshop consensus for vitamin D nutritional guidelines. J Steroid Biochem Mol Biol. 2007;103:204–5. doi: 10.1016/j.jsbmb.2006.12.071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Chowdhury R, Kunutsor S, Vitezova A, Oliver-Williams C, Chowdhury S, Kiefte-de-Jong JC, et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. Bmj. 2014;348:g1903. doi: 10.1136/bmj.g1903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, et al. Abdominal adiposity and coronary heart disease in women. JAMA. 1998;280:1843–8. doi: 10.1001/jama.280.21.1843. [DOI] [PubMed] [Google Scholar]
  • 24.Wamberg L, Kampmann U, Stodkilde-Jorgensen H, Rejnmark L, Pedersen SB, Richelsen B. Effects of vitamin D supplementation on body fat accumulation, inflammation, and metabolic risk factors in obese adults with low vitamin D levels - results from a randomized trial. Eur J Intern Med. 2013;24:644–9. doi: 10.1016/j.ejim.2013.03.005. [DOI] [PubMed] [Google Scholar]
  • 25.Aizer AA, Wilhite TJ, Chen MH, Graham PL, Choueiri TK, Hoffman KE, et al. Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer. 2014;120:1532–9. doi: 10.1002/cncr.28617. [DOI] [PubMed] [Google Scholar]
  • 26.Pappa HM, Mitchell PD, Jiang H, Kassiff S, Filip-Dhima R, DiFabio D, et al. Maintenance of Optimal Vitamin D Status in Children and Adolescents with Inflammatory Bowel Disease: A Randomized Clinical Trial Comparing Two Regimens. J Clin Endocrinol Metab. 2014:jc20134218. doi: 10.1210/jc.2013-4218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Imayama I, Ulrich CM, Alfano CM, Wang C, X L, Wener MH, et al. Effects of a caloric restriction weight loss diet and exercise on inflammatory biomarkers in overweight/obese postmenopausal women: a randomized controlled trial. Cancer Research. 2012;72:2314–26. doi: 10.1158/0008-5472.CAN-11-3092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Abbenhardt C, McTiernan A, Alfano CM, Wener MH, Campbell KL, Duggan C, et al. Effects on adiponectin and leptin after individual and combined diet and exercise interventions in postmenopausal women. J Intern Med. 2013;274:163–75. doi: 10.1111/joim.12062. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Mason C, Xiao L, Imayama I, Duggan C, Wang CY, Korde L, et al. Vitamin D3 supplementation during weight loss: a double-blind randomized controlled trial. Am J Clin Nutr. 2014;99:1015–25. doi: 10.3945/ajcn.113.073734. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Ashing-Giwa KT, Lim JW. Examining the impact of socioeconomic status and socioecologic stress on physical and mental health quality of life among breast cancer survivors. Oncol Nurs Forum. 2009;36:79–88. doi: 10.1188/09.ONF.79-88. [DOI] [PubMed] [Google Scholar]
  • 31.Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403. doi: 10.1056/NEJMoa012512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Ryan DH, Espeland MA, Foster GD, Haffner SM, Hubbard VS, Johnson KC, et al. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials. 2003;24:610–28. doi: 10.1016/s0197-2456(03)00064-3. [DOI] [PubMed] [Google Scholar]
  • 33.Mason C, Xiao L, Imayama I, Duggan C, Wang CY, Korde L, et al. Vitamin D3 supplementation during weight loss: a double-blind randomized controlled trial. Am J Clin Nutr. 2014 doi: 10.3945/ajcn.113.073734. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Hopkins MH, Owen J, Ahearn T, Fedirko V, Flanders WD, Jones DP, et al. Effects of supplemental vitamin D and calcium on biomarkers of inflammation in colorectal adenoma patients: a randomized, controlled clinical trial. Cancer prevention research (Philadelphia, Pa. 2011;4:1645–54. doi: 10.1158/1940-6207.CAPR-11-0105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovascular drug reviews. 2006;24:33–50. doi: 10.1111/j.1527-3466.2006.00033.x. [DOI] [PubMed] [Google Scholar]
  • 36.Yanez B, Thompson EH, Stanton AL. Quality of life among Latina breast cancer patients: a systematic review of the literature. J Cancer Surviv. 2011;5:191–207. doi: 10.1007/s11764-011-0171-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst. 2006;98:451–9. doi: 10.1093/jnci/djj101. [DOI] [PubMed] [Google Scholar]
  • 38.Feskanich D, Ma J, Fuchs CS, Kirkner GJ, Hankinson SE, Hollis BW, et al. Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev. 2004;13:1502–8. [PubMed] [Google Scholar]
  • 39.Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: longitudinal studies of serum vitamin D and colorectal cancer risk. Alimentary pharmacology & therapeutics. 2009;30:113–25. doi: 10.1111/j.1365-2036.2009.04022.x. [DOI] [PubMed] [Google Scholar]
  • 40.Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: serum vitamin D and breast cancer risk. Eur J Cancer. 2010;46:2196–205. doi: 10.1016/j.ejca.2010.03.037. [DOI] [PubMed] [Google Scholar]
  • 41.Mondul AM, Weinstein SJ, Mannisto S, Snyder K, Horst RL, Virtamo J, et al. Serum vitamin d and risk of bladder cancer. Cancer Res. 2010;70:9218–23. doi: 10.1158/0008-5472.CAN-10-0985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Chandler PD, Scott JB, Drake BF, Ng K, Manson JE, Rifai N, et al. Impact of vitamin d supplementation on inflammatory markers in african americans: results of a four-arm, randomized, placebo-controlled trial. Cancer prevention research (Philadelphia, Pa. 2014;7:218–25. doi: 10.1158/1940-6207.CAPR-13-0338-T. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Colditz GA, Willett WC, Stampfer MJ, Manson JE, Hennekens CH, Arky RA, et al. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol. 1990;132:501–13. doi: 10.1093/oxfordjournals.aje.a115686. [DOI] [PubMed] [Google Scholar]
  • 44.Das M, Tomar N, Sreenivas V, Gupta N, Goswami R. Effect of vitamin D supplementation on cathelicidin, IFN-gamma, IL-4 and Th1/Th2 transcription factors in young healthy females. Eur J Clin Nutr. 2014;68:338–43. doi: 10.1038/ejcn.2013.268. [DOI] [PubMed] [Google Scholar]
  • 45.Belenchia AM, Tosh AK, Hillman LS, Peterson CA. Correcting vitamin D insufficiency improves insulin sensitivity in obese adolescents: a randomized controlled trial. Am J Clin Nutr. 2013;97:774–81. doi: 10.3945/ajcn.112.050013. [DOI] [PubMed] [Google Scholar]
  • 46.Wang Y, Liu XJ, Robitaille L, Eintracht S, MacNamara E, Hoffer LJ. Effects of vitamin C and vitamin D administration on mood and distress in acutely hospitalized patients. Am J Clin Nutr. 2013;98:705–11. doi: 10.3945/ajcn.112.056366. [DOI] [PubMed] [Google Scholar]
  • 47.Jorde R, Sneve M, Torjesen PA, Figenschau Y, Goransson LG, Omdal R. No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine. 2010;50:175–80. doi: 10.1016/j.cyto.2009.12.006. [DOI] [PubMed] [Google Scholar]
  • 48.Yin K, Agrawal DK. Vitamin D and inflammatory diseases. Journal of inflammation research. 2014;7:69–87. doi: 10.2147/JIR.S63898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Abou-Raya A, Abou-Raya S, Helmii M. The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: a randomized placebo-controlled trial. J Rheumatol. 2013;40:265–72. doi: 10.3899/jrheum.111594. [DOI] [PubMed] [Google Scholar]
  • 50.Elshal MF, McCoy JP. Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. 2006;38:317. doi: 10.1016/j.ymeth.2005.11.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Staples E, Ingram RJM, Atherton JC, Robinson K. Optimising the quantification of cytokines present at low concentrations in small human mucosal tissue samples using Luminex assays. J Immunol Methods. 2013;394:1–9. doi: 10.1016/j.jim.2013.04.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.duPont NC, Wang K, Wadhwa PD, Culhane JF, Nelson EL. Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: Determinations of a panel of nine cytokines in clinical sample culture supernatants. Journal of Reproductive Immunology. 2005;66:175–91. doi: 10.1016/j.jri.2005.03.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Khan SS, Smith MS, Reda D, Suffredini AF, McCoy JP., Jr Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry B Clin Cytom. 2004;61:35–9. doi: 10.1002/cyto.b.20021. [DOI] [PubMed] [Google Scholar]
  • 54.Kellar KL, Kalwar RR, Dubois KA, Crouse D, Chafin WD, Kane BE. Multiplexed fluorescent bead-based immunoassays for quantitation of human cytokines in serum and culture supernatants. Cytometry. 2001;45:27–36. doi: 10.1002/1097-0320(20010901)45:1<27::aid-cyto1141>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  • 55.Ray CA, Bowsher RR, Smith WC, Devanarayan V, Willey MB, Brandt JT, et al. Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum. Journal of pharmaceutical and biomedical analysis. 2005;36:1037–44. doi: 10.1016/j.jpba.2004.05.024. [DOI] [PubMed] [Google Scholar]
  • 56.Wong HL, Pfeiffer RM, Fears TR, Vermeulen R, Ji S, Rabkin CS. Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons. Cancer Epidemiol Biomarkers Prev. 2008;17:3450–6. doi: 10.1158/1055-9965.EPI-08-0311. [DOI] [PubMed] [Google Scholar]

RESOURCES